News Sentiment

3681 sentiment intelligence

SinoMab BioScience Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report RSS feed
Weighted score 50 Balanced news tone 3 relevant articles
Exchange HKG Hong Kong
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.19 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 3

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-8.5% over one week, -7.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis

Market Reaction

Price moving ahead of tone

57/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -8.5% Price reacting lower
Trend fit Trend inactive -7.8% over four weeks
Fair value -22.5% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 0
Neutral 3
Negative 0

Relevance

Why the article matched

Direct first
Direct company coverage 3
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Media OutReach Newswire 1
ACN Newswire 1
South China Morning Post 1

Event Lens

What the news is about

Classified themes
Market update 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-3 of 3